exporting, directly or indirectly dealing in pharmaceutical products, compound or formulation containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride in combination or Vildagliptin in combination with ... stock of infringing pharmaceutical formulations, compound or combinations comprising Vildagliptin alone and/or Vildagliptin in combination with Metformin Hydrochloride or any other compound or formulation
marketing pharmaceutical products containing the
active pharmaceutical ingredient (API) Vildagliptin (subject matter of
the suit patent), under co-marketing agreement with Plaintiff ... superior and high quality. Plaintiff no. 2 markets in
India Vidagliptin and Vildagliptin + Metformin Hydrochloride in
combination under the brands GALVUS and GALVUSMET
respectively. Similarly
Single Judge
has noted that the patent relates to a pharmaceutical product Vildagliptin.
It treats Type 2 Diabetes Mellitus. The learned Single Judge has noted ... have three
pending patent applications before the Indian Patent Office relating to
Vildagliptin formulations, Vildagliptin and Metformin hydrochloride
formulations under the brands GALVUS and GALVUSMET
exporting, directly or indirectly dealing in pharmaceutical products, compound or formulation containing Vildagliptin alone or Vildagliptin + Metformin Hydrochloride in combination or Vildagliptin in combination with ... stock of infringing pharmaceutical formulations, compound or combinations comprising Vildagliptin alone and/or Vildagliptin in combination with Metformin Hydrochloride or any other compound or formulation
patent which covers the Type 2
Diabetes Mellitus (T2DM) compound named 'Vildagliptin'. The sum
and substance of the ground taken by the Defendant
